| Antigen: | CD79b |
| Clone: | B29/123 |
| Subclass | IgG2b |
| Species Raised In: | Mouse |
| Immunogen: | Synthetic peptide representing the c-terminus from residue 215 of the murine B29 polypeptide. |
| Epitope: | CGEVKWSVGEHPGQE |
| Cross Reactivity: | Human |
| Applications: | Frozen, Paraffin embedded, Western |
| Growth Conditions: | RPMI 1640 + 10% FCS + penicillin (100U/ml) + streptomycin (100mg/l) + glutamine (2mM) + HAT |
| Fusion Partner: | NS1 |
| Relevance: | The B-cell Antigen receptor constitutes a disulphide linked heterodimer, consisting of CD79a (mb1) and CD79b / B29 polypeptides which are non-covalently associated with membrane bound immunoglobulins on B-cells. CD79a first appears at pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in B-cell lymphomas, in B-cell lines, the majority of acute leukemias of precursor B-cell type and in some myelomas. The CD79a/b heterodimer interacts with at least one tyrosine kinase (Lyn). The induction of tyrosine kinase activity after antigen binding leads to phosphorylation of the CD79a/b dimer, and also of other molecules, thereby initiating intracellular signalling. |
| Notes: | Please note this cell line has not been weaned out of HAT. Ultroser G can be used at 1% if the cells are not growing well. |
© Cancer Research Technology 2012